EGFR and neoplasm: We thus treated GL26nu and GL26B6V cells (unexposed or exposed to strong anti-tumor T cell activity, respectively) with cyclopamine, and with Tarceva (Erlotinib), an inhibitor of Egfr signaling used here as a control.